SkyePharma has signed a second agreement to conduct a feasibility study with RespiVert Ltd., a Janssen Biotech company. The agreement is for a feasibility study to develop a dry powder inhaler (DPI) dosage form for a RespiVert compound and follows the successful completion of a similar program on another RespiVert compound. Both projects are aimed at developing new therapeutic options for patients living with severe, chronic respiratory diseases including chronic obstructive pulmonary disease (C...